Differences between oral antidiabetic drugs;Forskjeller mellom perorale antidiabetika

Tidsskrift for den Norske Laegeforening

Volumn 123, Issue 6, 2003, Pages 808-809

  Bleskestad, Inger Hjørdis ^a   Birkeland, Kåre Inge ^b  

^a Sentralsjukehuset ^*  (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; CYCLOHEXANE DERIVATIVE; DRUG DERIVATIVE; INSULIN; PHENYLALANINE; PIPERIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE;

DRUG EFFECT; DRUG MECHANISM; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT SURVEY; ARTICLE; COMPARATIVE STUDY; DIABETES MELLITUS; HUMAN; ORAL DRUG ADMINISTRATION; SECRETION;

ADMINISTRATION, ORAL; CARBAMATES; CYCLOHEXANES; DIABETES MELLITUS; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PHENYLALANINE; PIPERIDINES; SULFONYLUREA COMPOUNDS;

EID: 0038317916     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. Diabetic Med 2001; 18: 395-401.
2. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202-7.
3. Åsvold BO, Jonsbu M, Grill V. Gir sulfonylurea økt kardiovaskulær risiko hos type 2-diabetikere? Tidsskr Nor Lægeforen 2000; 120: 2560-4.
4. Carlsen SM. Sulfonylureaindusert hypoglykemi. Tidsskr Nor Lægeforen 1997; 117: 3079-82.
5. Holstein A, Plaschke A, Egberts E. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17: 467-73.
6. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001; 30: 909-33.
7. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111-6.
8. Silvio EI. Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 2002; 287: 360-72.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.